EHA 2024 preview – Shattuck has a heart scare
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
AACR 2024 – Medicenna looks for a cytokine renaissance
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
AACR 2024 – a first look at Astra’s ATM inhibitor
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
AACR 2024 – Vincerx overreaches
The company's comparison of its ADCs to Enhertu seems farfetched.
